NASDAQ:CRNX - Crinetics Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.00
  • Forecasted Upside: 151.08 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.94
▼ -0.66 (-4.52%)
1 month | 3 months | 12 months
Get New Crinetics Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRNX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$35.00
▲ +151.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $35.00, with a high forecast of $38.00 and a low forecast of $30.00. The average price target represents a 151.08% upside from the last price of $13.94.
Buy
The current consensus among 4 investment analysts is to buy stock in Crinetics Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
i
5/22/2020HC WainwrightReiterated RatingBuy$35.00 ➝ $30.00High
i
Rating by Douglas Tsao at HC Wainwright
5/11/2020Cantor FitzgeraldBoost Price TargetAccumulate ➝ Overweight$28.00 ➝ $38.00High
i
Rating by C. Duncan at Cantor Fitzgerald
4/3/2020HC WainwrightReiterated RatingBuy$35.00Medium
i
Rating by Douglas Tsao at HC Wainwright
3/18/2020Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by C. Duncan at Cantor Fitzgerald
3/11/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by D. Tsao at HC Wainwright
12/23/2019Roth CapitalInitiated CoverageBuy$37.00High
i
Rating by Y. Rahimi at Roth Capital
11/21/2019HC WainwrightReiterated RatingBuy$35.00Low
i
Rating by Douglas Tsao at HC Wainwright
4/16/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by D. Tsao at HC Wainwright
3/11/2019Cantor FitzgeraldInitiated CoverageOverweight$40.00High
i
Rating by C. Duncan at Cantor Fitzgerald
2/14/2019HC WainwrightInitiated CoverageBuy$35.00Low
i
Rating by D. Tsao at HC Wainwright
11/14/2018JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.00High
i
8/13/2018SVB LeerinkInitiated CoverageOutperform$43.00High
i
Rating by J. Schwartz at SVB Leerink LLC
8/13/2018JPMorgan Chase & Co.Initiated CoverageNeutral$29.00High
i
8/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight$40.00High
i
(Data available from 10/23/2015 forward)
Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $13.94
$13.54
$14.91

50 Day Range

MA: $15.41
$13.62
$17.46

52 Week Range

Now: $13.94
$10.63
$26.67

Volume

169,847 shs

Average Volume

138,279 shs

Market Capitalization

$458.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16